Alpha1Health.com | Information for the New Alpha-1 Patient | About ARALAST

ARALAST Therapy

Aralast

ARALAST is a therapy for patients with congenital alpha-1 antitrypsin (AAT) deficiency* who have been diagnosed with clinically evident emphysema. ARALAST is a chronic augmentation therapy, meaning it is designed to raise the level of AAT protein in your blood.

*Also known as Alpha-1, AAT Deficiency, AATD, A1-PI deficiency, alpha-1 proteinase deficiency, A1AD, or hereditary or genetic emphysema.

Healthcare professionals prescribe ARALAST for many important reasons. ARALAST...

  • Raises AAT levels in both blood and lungs
  • Has an acceptable tolerability profile; in a pivotal study1, no serious side effects were reported
  • Is administered once a week, often in your home
  • Is made using a two-step viral treatment process to reduce the risk of viral transmission
  • Is provided by Baxter Healthcare Corporation, a company with a long history of innovation and safety in blood products
  • Is supported by Baxter's patient education and support programs.

In this section of the website, you can learn more about ARALAST and about all the reasons ARALAST may be a good choice for you.

ARALAST [Alpha1-Proteinase Inhibitor (Human)]

ARALAST is indicated for chronic augmentation therapy in patients having congenital deficiency of A1-PI with clinically evident emphysema. ARALAST is not indicated as therapy for lung disease patients in whom congenital A1-PI deficiency has not been established.

Important Safety Information

  • ARALAST is contraindicated in individuals with selective IgA deficiencies (IgA level less than 15mg/dL) who have known antibody against IgA, since they may experience severe reactions, including a severe, potentially life-threatening allergic reaction to IgA, which may be present.
  • ARALAST is made from human plasma. It may carry a risk of transmitting infectious agents, e.g. viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent.
  • The most common symptoms during the clinical study were headache (0.3%) and sleepiness (0.3%). Post market adverse event data have indicated reports of infusion site pain associated with the administration of ARALAST.

Please review the ARALAST Full Prescribing Information

  1. Stoller JK, Rouhani F, Brantly M, et al. Biochemical efficacy and safety of a new pooled human plasma alpha (1)-antitrypsin, Respitin. Chest. 2002; 122:66-74.]
adobe reader To view PDF, you will need Adobe® Acrobat® Reader® software.